Fact.MR’s revised sepsis diagnostics market study forecasts a healthy growth trajectory for FY 2021-22 and beyond, with the market expected to increase at a CAGR worth around 8% through 2031. Growth prospects were further underpinned amidst the coronavirus pandemic, attributed to the onset of pneumonia-induced sepsis and consequent fatalities.
For detailed insights on enhancing your product footprint, request for a sample here – https://www.factmr.com/connectus/sample?flag=S&rep_id=391
According to the report, the market is expected to yield high short-term gains, generating over US$ 700 million in revenue by 2026. These are largely attributed to ongoing research & development initiatives amid a general upswing in ICU and hospital admission-induced sepsis amongst patients. Manufacturers are incorporating the latest automated technologies to ensure precision and timely diagnostics.
Epidemiologically, an estimated 22 cases of childhood sepsis per 100,000 person-years and 2,202 cases of neonatal sepsis per 100,000 live births occur. This translates into 1.2 million cases of childhood sepsis annually.
For critical insights on this market, request for methodology here – https://www.factmr.com/connectus/sample?flag=RM&rep_id=391
For in-depth competitive analysis, buy now – https://www.factmr.com/checkout/391
The global sepsis diagnostics market is interspersed with the presence of a large number of diagnostic service providers, rendering it highly competitive in nature. Amongst all the expansion strategies deployed, offering technologically advanced solutions by virtue of conducting immense R&D remains the core objective.
- For instance, Luminex Corporation, a pioneer in diagnostics testing, offers the VERIGENE® and VERIGENE® II Systems, specifically designed to target infections in the blood stream, respiratory tract and gastrointestinal tract. These systems use highly automated workflows, helping perform extraction, amplification, hybridization and detection, helping improve clinical outcomes by preventing the onset of sepsis.
- Likewise, Abionic SA offers the abioSCOPE, a non-fluidic immunoassay technology, which was tested across 14 European hospitals on several hundred patients, with doctors confirming that in over 85% of the cases, sepsis detection was possible more than 24 hours prior as compared to standard care. The solution was approved for clinical trials across U.S. hospitals in 2020.
Read More Trending and Similar Reports from Fact.MR – https://www.globenewswire.com/en/news-release/2019/07/26/1892334/0/en/Optometry-Equipment-Sales-Surge-in-Line-with-Industry-s-Focus-on-Easy-Access-and-Competitive-Price-Point-Says-Fact-MR.html
Explore Fact.MR’s Comprehensive Coverage on Healthcare Landscape
Bartter Syndrome Treatment Market Forecast, Trend Analysis & Competition Tracking – Global Market Insights 2018 to 2028- https://www.factmr.com/report/2192/bartter-syndrome-treatment-market
Antibacterial Washcloth Market Forecast, Trend Analysis & Competition Tracking – Global Market Insights 2018 to 2028- https://www.factmr.com/report/2190/antibacterial-washcloth-market
Acromegaly Treatment Market Forecast, Trend Analysis & Competition Tracking – Global Market Insights 2018 to 2028- https://www.factmr.com/report/2191/acromegaly-treatment-market
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.
US Sales Office:
11140 Rockville Pike
Rockville, MD 20852
Tel: +1 (628) 251-1583